BioSpace News Archive

Cybin Inc. today announced that it has partnered with Clinilabs Drug Development Corporation to carry out the Company’s Phase 1/2a clinical trial of CYB003, a proprietary deuterated psilocybin analog.

Tvardi Therapeutics, Inc. today announced that its lead product, TTI-101, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of hepatocellular carcinoma (HCC).

Twist Bioscience Corporation today announced the promotion of Tracey Mullen, MBA to senior vice president of operations and Nimisha Srivastava, Ph.D. to senior vice president of research and development.

Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2022 financial results will be released on Thursday, May 5, 2022, after the close of the stock market.

Astria Therapeutics, Inc. today announced that it will share new preclinical data for STAR-0215 in a presentation titled “Development of STAR-0215: An Engineered IgG1 Monoclonal Antibody Targeting Plasma Kallikrein for the Prevention of HAE” at the 2022 Fc Receptor and IgG Targeted Therapies Conference which takes place April 26-28 in Boston, Massachusetts.

ENDRA Life Sciences Inc. announces that the Company has raised $8.7 million in gross proceeds year-to-date from the sale of common stock through its at-the-market (ATM) equity facility.

FSD Pharma Inc. announced the appointment of David Allan and John McGraw, PhD, MSc, to the Company’s Advisory Board.

Blue Water Vaccines Inc. today issued the below statement regarding its Form 8-K filed with the Securities and Exchange Commission (“SEC”) on April 20, 2022, which included a presentation (the “WVC presentation”) delivered by the Company at the World Vaccine Congress 2022 in Washington, DC.

Terran Biosciences, Inc. has entered into an agreement with Sanofi S.A. (“Sanofi”) for worldwide exclusive rights to develop and commercialize two late-stage CNS pipeline assets.

NRx Pharmaceuticals Files New Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil) in Subgroup of Patients with Critical COVID-19 with Respiratory Failure.